Recent concerns about availability and authenticity of certain drugs have generated news headlines worldwide and raised anxiety levels for some cancer patients and their families.
Sylvia Bartel, RPh, MHP, Dana-Farber’s vice president of Pharmacy, says that although the cause of the two problems is unrelated, it underscores the need for continuous and careful monitoring and management of the Institute’s medications. Read more
Harold J. Burstein, MD, PhD, a Dana-Farber breast cancer specialist, discusses some of the important studies presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium.
The five-day meeting includes more than 1,000 scientific presentations, seminars, and posters, with a focus on emerging treatments in hard-to-treat populations, patients with metastatic breast cancer, and breast cancer prevention and risk.
Around 8,000 breast cancer experts from 90 countries are attending the symposium to learn about the latest developments in breast cancer care and research.